Corcept Therapeutics Inc
CORT
Market Cap$8.22B
Close$
$192.69
175.4% upside
Current Fair Value
175.4% upsideUndervalued by 175.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.22 Billion |
|---|---|
| Enterprise Value | $8.16 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.35 |
| Beta | 0.21 |
| Outstanding Shares | 104,106,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 60.78 |
|---|---|
| PEG | -225.75 |
| Price to Sales | 11.66 |
| Price to Book Ratio | 11.66 |
| Enterprise Value to Revenue | 11.9 |
| Enterprise Value to EBIT | 73.57 |
| Enterprise Value to Net Income | 61 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...